Opinion|Videos|December 3, 2024
Clinical Pearls Surrounding the Use of Bispecifics in R/R MM
Author(s)Omar Nadeem, MD
Dr Nadeem discusses his approach to sequencing bispecifics vs chimeric antigen receptor T-cell therapies, including B-cell maturation antigen (BCMA) and non-BCMA bispecifics, and the factors he considers, followed by key takeaways from a recent meeting on bispecifics in relapsed/refractory multiple myeloma, focusing on dosing, adverse event management, and clinical pearls for oncologists.
Advertisement
Episodes in this series
Video content above is prompted by the following
- How do you approach sequencing (bispecifics vs chimeric antigen receptor T-cell or B-cell maturation antigen [BCMA] bispecific vs non-BCMA bispecific) in your practice?
- What factors do you consider?
- Please share your key takeaways from that meeting, especially surrounding the use of bispecifics (dosing, adverse event management) in relapsed/refractor multiple myeloma (R/R MM).
- What clinical pearls can you share with fellow medical oncologists considering the use of bispecifics in R/R MM?
Advertisement
Related to this article
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5